- NOVO_B: Oral Wegovy (semaglutide) approved Dec 2025, launched Jan 2026 alongside existing Wegovy injection; pricing uses commercial-insurance discounts and various self-pay options.
- Novo Nordisk sued Eli Lilly in New Jersey, alleging false advertising: Lilly’s ads compare Lilly high doses to lower Novo doses while omitting Novo’s newer higher-dose Wegovy 7.2 mg and Ozempic 2 mg.
TradingView
Key facts: Oral Wegovy launched with tiers; Novo Nordisk sues Lilly
- Sources
- TradingView
- Active symbols
- OMXCOP:NOVO_B
- Language
- English
NOVO_B: Oral Wegovy (semaglutide) approved Dec 2025, launched Jan 2026 alongside existing Wegovy injection; pricing uses commercial-insurance discounts and various self-pay options